Adults with type 2 diabetes who have not achieved adequate blood sugar control despite multiple treatments may qualify for a research study evaluating an investigational oral medication targeting cortisol-related metabolic dysfunction.
Adults with type 2 diabetes who have not achieved adequate blood sugar control despite multiple treatments may qualify for a research study evaluating an investigational oral medication targeting cortisol-related metabolic dysfunction.
This research study is evaluating an investigational medication called clofutriben, which works by inhibiting an enzyme involved in cortisol regulation. By reducing the effects of excess cortisol, this therapy may help improve blood sugar control and overall metabolic health.
The purpose of this study is to better understand how well this medication works compared to placebo (inactive treatment), and to evaluate its safety in people with type 2 diabetes and elevated cortisol levels.
You may be able to join if you:
If you’re interested in participating or want to learn more, contact us today to see if you may qualify.
Individuals with generalized anxiety disorder (GAD) who experience ongoing worry, stress, or difficulty managing anxiety symptoms may qualify for a
Individuals with chronic obstructive pulmonary disease (COPD) who continue to experience symptoms or flare-ups despite treatment may qualify for a
Adults 18 to 65 years of age with Major Depressive Disorder (MDD) may qualify for a clinical research study evaluating
Adults 40–75 who have COPD and experienced a flare-up in the past year may qualify for a study evaluating an
Adults 18 and older living with post-traumatic stress disorder (PTSD) may qualify for a clinical research study evaluating an investigational
Researchers are studying an investigational medication to see how effective it may be in reducing risk of heart failure for